Search research articles
Contact Us
Filters
Showing results (71-80 of 103) with videos related to
Page
of 11
Sort By:
Annals of Hematology
|
August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu, Thomas Martin, Katja Weisel, et al.
Blood Cancer Discovery
|
September 28, 2023
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, et al.
Science Advances
|
November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Sherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Blood Cancer Journal
|
January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Vikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Leukemia
|
May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Joseph Mikhael, Joshua Richter, Ravi Vij, et al.
Current Medical Research and Opinion
|
June 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Naresh Bumma, Hans C Lee, Joshua Richter, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Ejhaem
|
July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma
Paul G Richardson, Sundar Jagannath, Ajai Chari, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 103) with videos related to
Sort By:
Page
of 11
Annals of Hematology
|
August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu, Thomas Martin, Katja Weisel, et al.
Blood Cancer Discovery
|
September 28, 2023
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, et al.
Science Advances
|
November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Sherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Blood Cancer Journal
|
January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Vikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Leukemia
|
May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Joseph Mikhael, Joshua Richter, Ravi Vij, et al.
Current Medical Research and Opinion
|
June 25, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Naresh Bumma, Hans C Lee, Joshua Richter, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Ejhaem
|
July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma
Paul G Richardson, Sundar Jagannath, Ajai Chari, et al.
Page
of 11